Namita Khanna
Advanced in Pseudomyxoma Peritonei

Dr. Namita Khanna

Oncology
Emory Clinic At 1365 Clifton Road
1365 Clifton Road Northeast, BldgA, 
Atlanta, GA 
Offers Telehealth
25 Years of Experience
Advanced in Pseudomyxoma Peritonei
Emory Clinic At 1365 Clifton Road
1365 Clifton Road Northeast, BldgA, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Namita Khanna is an Oncologist in Atlanta, Georgia. Dr. Khanna has been practicing medicine for over 25 years and is rated as an Advanced provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Ovarian Carcinosarcoma, Cervical Cancer, Sertoli-Leydig Cell Tumor, Ovarian Cancer, and Hysterectomy.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Calcutta-IND, 2000
Residency
Jackson Memorial Hospital
Specialties
Oncology
Licenses
Obstetrics & Gynecology in FL
Board Certifications
American Board Of Obstetrics And Gynecology, 2012
Fellowships
Jackson Memorial Hospital
Hospital Affiliations
Emory University Hospital Midtown
Emory Johns Creek Hospital
Emory University Hospital
Languages Spoken
English
Hindi
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Emory Clinic at 1365 Clifton Road
1365 Clifton Road Northeast, BldgA, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 5 Less Clinical Trials

27 Total Publications

Neighborhood disorder and ovarian cancer survival in black women.
Neighborhood disorder and ovarian cancer survival in black women.
Journal: American journal of epidemiology
Published: October 03, 2024
Similar Doctors
Advanced in Pseudomyxoma Peritonei
Dr. Natalie S. Godbee
Gynecologic Oncology | Oncology
Advanced in Pseudomyxoma Peritonei
Dr. Natalie S. Godbee
Gynecologic Oncology | Oncology

City Of Hope Medical Group Of Georgia LLC

600 Celebrate Life Pkwy, 
Newnan, GA 
 (37.8 miles away)
770-400-6080
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Natalie Godbee is a Gynecologic Oncologist and an Oncologist in Newnan, Georgia. Dr. Godbee is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Testicular Yolk Sac Tumor, and Ovarian Carcinosarcoma. Dr. Godbee is currently accepting new patients.

Advanced in Pseudomyxoma Peritonei
Dr. Eyal Meiri
Oncology
Advanced in Pseudomyxoma Peritonei
Dr. Eyal Meiri
Oncology

Piedmont Providers LLC

1968 Peachtree Nw Rd, 
Atlanta, GA 
 (4.4 miles away)
404-605-5000
Languages Spoken:
English, Hebrew, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Eyal Meiri is an Oncologist in Atlanta, Georgia. Dr. Meiri is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Familial Pancreatic Cancer, and Colorectal Cancer. Dr. Meiri is currently accepting new patients.

Advanced in Pseudomyxoma Peritonei
Dr. Shahin A. Chowdhury
Oncology
Advanced in Pseudomyxoma Peritonei
Dr. Shahin A. Chowdhury
Oncology

City Of Hope Medical Group Of Georgia LLC

600 Celebrate Life Pkwy, 
Newnan, GA 
 (37.8 miles away)
770-400-6080
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shahin Chowdhury is an Oncologist in Newnan, Georgia. Dr. Chowdhury is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Pancreatic Cancer. Dr. Chowdhury is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khanna's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 26 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile